.png)
TL;DRA rebate contract (Rabattvertrag) is a discount agreement between a statutory health insurance fund (gesetzliche Krankenkasse) and a pharmaceutical company under §130a Abs. 8 SGB V. The fund receives a rebate on the medicines dispensed at its expense, and in return the pharmacy is steered toward dispensing the contracted product.
The legal basis is short and precise. §130a Abs. 8 Satz 1 SGB V provides that die Krankenkassen oder ihre Verbände, the sickness funds or their associations, may agree rebates with pharmaceutical companies for the medicines dispensed at their expense. The statute names three permitted structures: a volume-tiered price reduction (mengenbezogene Staffelung des Preisnachlasses), an agreed annual turnover volume with subsequent settlement, and reimbursement linked to measurable therapeutic outcomes (messbare Therapieerfolge). The rebate itself is confidential, negotiated between the two parties, and does not appear as a line item on the pharmacy invoice.
§130a Abs. 8 SGB V sets a target term: the agreement soll für eine Laufzeit von zwei Jahren erfolgen, it should run for two years. This is a Soll-Vorschrift, a strong default rather than an absolute command, so two years is the norm and a deviation needs justification. That two-year rhythm is why generic supply relationships turn over on a roughly biennial cycle, and why a manufacturer that loses a contract can lose the bulk of a product's volume within a supply period.
This is the part that decides whether the rebate has any value, and it sits in §129 Abs. 1 SGB V, not in §130a. Where a doctor prescribes only by active ingredient, or has not excluded substitution by crossing the aut-idem field, the pharmacy must dispense a product identical in strength (Wirkstärke) and pack size (Packungsgröße), licensed for the same indication (Anwendungsgebiet), and of the same or an interchangeable dosage form (Darreichungsform). Within that substitutable set, priority goes to a product for which a §130a Abs. 8 agreement exists with effect for that patient's fund, unless the framework contract under §129 Abs. 5 provides otherwise.
The dispensing decision follows a fixed order.
Customer conversations show these three terms used as if they were interchangeable. They are not. A rebate contract is the outcome, a discount agreement. The Ausschreibung (exclusive tender) and the Open-House-Vertrag (open house contract) are two different procedures for arriving at one.
| Rebate contract | Ausschreibung (exclusive tender) | Open-House-Vertrag | |
|---|---|---|---|
| What it is | The rebate agreement itself under §130a Abs. 8 SGB V | A procedure to select one or few rebate partners | A procedure admitting every willing supplier on fixed terms |
| Selection decision | Not a category of selection; it is the resulting contract | Yes, the fund selects the winner or winners | None, this is its defining feature |
| Partners per active ingredient and fund | Depends on the route used to award it | Typically one | Unlimited, several can hold a contract at once |
| Joining later | Set by the awarding procedure | No, the window closes at the deadline | Yes, at any time on identical terms |
| Procurement law | Depends on the route | Applies in full | Does not apply, per ECJ C-410/14 |
| Pharmacy effect | Substitution priority under §129 Abs. 1 SGB V | One rebate partner to dispense | Several rebated products coexist, the framework contract decides inside the set |
In short, a rebate contract can be awarded through an exclusive tender or through an open house model. The Open-House-Vertrag entry explains why the open house route sits outside procurement law and how several partners can be rebated at the same time.
Two effects reach the insured person. First, they usually receive one specific manufacturer's product, which can change when the contract is renewed even though the active ingredient stays the same. Second, and this is the tangible incentive, §31 Abs. 3 SGB V allows the fund to halve or waive the statutory co-payment (Zuzahlung) for a product covered by a §130a Abs. 8 agreement, where savings are expected. The waiver is a fund's option, not an automatic entitlement, so a rebated product is not always free of co-payment.
Rebate status reaches the platform through the licensed ABDA article master data, in two places on the article detail page.
One honest limitation, flagged by our own field survey: the structure exists, but we have not verified its coverage. In three samples the rebate-contract tab was empty. That was expected in each case, because the field is populated only for a generic currently under contract and actually in distribution, and the samples were an OTC brand, an originator, and a discontinued generic. An empty tab therefore tells you nothing about completeness either way. If rebate coverage is decision-relevant for you, ask us to demonstrate it against your own PZNs rather than taking a coverage claim on trust.
